Galmed Pharmaceuticals
GLMD
14 hedge funds and large institutions have $2.47M invested in Galmed Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less funds holding
Funds holding: 15 → 14 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
31% less capital invested
Capital invested by funds: $3.56M → $2.47M (-$1.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$60.5K |
| 2 |
CAD
Craig A. Drill
|
+$52.9K |
| 3 |
WJA
Williams Jones & Associates
New York
|
+$52.9K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$30.2K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
+$7.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$484K |
| 2 |
PA
Perceptive Advisors
New York
|
-$369K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$75.6K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$66K |
| 5 |
Goldman Sachs
New York
|
-$58K |
GLMD Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2016, worth a combined $2.47M — down 31% from $3.56M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $60.5K. The largest seller was 683 Capital Management, cutting an estimated $484K.
- 14 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2016, down from 15 in Q1 2016.
- Funds reported $2.47M of Galmed Pharmaceuticals stock for Q2 2016, down 31% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q2 2016 and 4 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q2 2016 was Renaissance Technologies, an estimated $60.5K added.
- The largest Galmed Pharmaceuticals seller in Q2 2016 was 683 Capital Management, an estimated $484K sold.
Based on aggregated 13F filings for Q2 2016.